ViaCyte logo

ViaCyte

ID: 5319165

ViaCyte is a biotechnology company using stem cells to create pancreatic beta cell precursors for treating diabetes.

16

Funding Rounds

$328.8m

Money raised

Overview

ViaCyte is a biotechnology company using stem cells to create pancreatic beta cell precursors for treating diabetes.

Unlock Complete Company Intelligence

Access comprehensive data and insights available only to Seedtable members

Financial Details

  • • Complete funding history and valuations
  • • Revenue estimates and financial metrics
  • • Investment round details and terms

People & Contacts

  • • Complete leadership team profiles
  • • Contact information and email addresses
  • • Board members and advisors

Market Intelligence

  • • Competitive landscape analysis
  • • Market position and growth metrics
  • • Industry benchmarking data

Premium Tools

  • • Export data and generate reports
  • • Save companies to custom watchlists
  • • API access for data integration

Join 10,000+ Professionals

Trusted by investors, founders, and analysts worldwide

Access detailed insights on 71,000+ companies worldwide

Funding

Funding series

Funding Series Analysis

The company ViaCyte has raised a total of $197m in funding over 16 rounds.

Key Insights:

  • ViaCyte Series D round (extension), June 2021: $45m
  • ViaCyte Series D round, May 2020: $27m
  • ViaCyte Series D round, November 2018: $80m
  • ViaCyte Series C round: $25m
  • ViaCyte funding round, May 2006: $20m
  • ViaCyte funding round, May 2017: $10m
  • ViaCyte Convertible note, September 2018: $10m
  • ViaCyte Grant (money), December 2017: $1.4m
  • ViaCyte Grant (money), July 2016: $3.9m
  • ViaCyte Grant (money), September 2014: $16.6m
  • ViaCyte Venture round, August 2014: $20m
  • ViaCyte Series C round, August 2014: $5.4m
  • ViaCyte Inc. funding round, April 2021: $53.9m
  • ViaCyte Inc. funding round, July 2013: $10.6m